Document:

EXHIBIT 10.61

                         EXECUTIVE EMPLOYMENT AGREEMENT

       THIS EXECUTIVE  EMPLOYMENT AGREEMENT (the "Agreement") dated as of August
1, 1999, is made by and between  Positron  Corporation a Texas  Corporation (the
"Company"), and Mr. Gary H. Brooks (the "Executive").

       The Company now wishes to employ the Executive  and the Executive  wishes
to accept such employment, subject to the terms and conditions hereof.

       Accordingly, the parties agree as follows:

       1.     TERM OF EMPLOYMENT. The initial term of the Executive's employment
under this Agreement (the initial "Term") commenced on January 22, 1999 and will
end on June 15, 2000,  unless sooner  terminated as herein provided.  As of June
15, 2000,  the  Executive  shall be employed for rolling (6) six month  periods,
whereby  the  Executive's  term  of  employment  shall  be (6) six  months  on a
continuing basis.

              2.     EMPLOYMENT, DUTIES AND ACCEPTANCE.

              2.1.   EMPLOYMENT BY THE COMPANY.  The Company, for itself and its
affiliates,  employs the Executive to render  services in such capacities as the
Board of  Directors  of the Company  ("Board")  may assign  and,  in  connection
therewith,  to  perform  such  duties  as are  consistent  with the  Executive's
appointment  and as the  Board of  Directors  of the  Company  shall  reasonably
direct.  The parties agree and  acknowledge  that  Executive's  services will be
rendered on a full time basis on and after June 15, 1999. The Executive shall be
initially  appointed to the  position of President of the Company.  In addition,
the company will nominate  Executive to serve as a member of the Board.  Subject
to Section 5.1.1 hereof,  the Executive's  expenditure of reasonable  amounts of
time for personal  business,  charitable or professional  activities will not be
deemed as a breach of his undertaking to provide full-time  services  hereunder,
provided that such  activities do not interfere  materially with the Executive's
ability to render such services.

              2.2.   ACCEPTANCE OF EMPLOYMENT  BY THE  EXECUTIVE.  The Executive
accepts  such  employment  and shall render the services  described  above.  The
Executive  shall also serve during all or any part of the Term as an officer and
director  of the  Company and of any of its  affiliates  without any  additional
compensation therefor other than that specified in this Agreement.

              2.3.   PLACE OF EMPLOYMENT. Executive shall relocate his principal
residence at the Company's expense as provided in Section 2.4 hereof to a within
reasonable   commuting  distance  of  the  Company's   corporate   headquarters.
Notwithstanding  the foregoing,  the Executive  acknowledges and agrees that the
nature of his duties to be performed here under are such that he may be required
to travel  extensively  both throughout the United States and abroad and in some
cases  spend   certain   limited   periods  of  time  away  from  the  corporate
headquarters,  and the Executive agrees to do so as is necessary or desirable to
perform his duties here under in a fully professional  manner to the best of his
ability.

<PAGE>

              2.4.   RELOCATION.  In the event that the Executive  relocated his
principal  residence as provided by Section 2.3 hereof, the Company will provide
an   amount   not  to   exceed   $20,000.00   as   reimbursement   of  costs  of
moving/storing/packing  the  Executive's  household  goods,  as well as  interim
travel expenses,  temporary  living  expenses,  etc. The Executive shall provide
receipts to the company to support the reimbursement requested.

       3.     COMPENSATION.

              3.1.   SALARY,  BONUSES,  LIFE INSURANCE.  As compensation for all
services to be rendered  pursuant to this  Agreement,  the Company shall pay the
Executive  as follows:  For the period of January 22, 1999 to June 15,  1999,  a
base salary in the gross amount of $1,000.00 per month;  for the period June 15,
1999 through August 30, 1999, a base salary in the gross amount of $3,416.67 per
month;  on and  after  September  1,  1999,  a base  salary  of  $185,000  on an
annualized  basis.  All base  salary is subject to  withholding  and  authorized
deductions and payable in accordance with the payroll policies of the Company as
from time to time in effect.  In addition to the Annual  Salary,  the  Executive
shall be awarded (no less frequently than annually) to such bonuses,  if any, as
the Board of  Directors  of the  Company  may,  from  time to time,  in its sole
discretion award.

              3.2.   ANNUAL  REVIEW.  Commencing  June  15,  2000  and  annually
thereafter during the Term, the Annual Salary shall be reviewed by the Board and
may be adjusted  (but in no event to an amount less than the Annual  Salary then
in effect)  for the then  upcoming  year,  if the Board in its sole  discretion,
determine that such adjustment is warranted.

              3.3.   PARTICIPATION  IN EMPLOYEE  BENEFIT  PLANS.  The  Executive
shall be entitled during the Term, if and to the extent eligible, to participate
in the Company's  group benefit plans including  life,  hospitalization  or long
term disability insurance plans, health program, pension plan or similar benefit
plans of the Company,  which may be available to other senior  executives of the
Company on generally the same terms as such other executives.

              3.4.   EXPENSES. Subject to such policies as may from time to time
be established by the Company,  the Company shall pay or reimburse the Executive
for all reasonable  business expenses actually incurred or paid by the Executive
during  the Term in the  performance  of the  Executive's  services  under  this
Agreement,  upon  presentation  of expense  statements or vouchers or such other
supporting information as the Company may reasonably require.

              3.5.   AUTOMOBILE.  The  Company  shall  pay to the  Executive  an
automobile  allowance  in the  amount of $500 per month  during  the term of the
Executive's employment.

              3.6.   EQUITY  PARTICIPATION/STOCK  OPTIONS. Pursuant to action of
the Board of Directors at its meeting held on June 15, 1999, the Executive shall
be provided with an opportunity to purchase a common stock purchase  warrant for
3,000,000  shares of the Company's  common stock  exercisable at $0.30 per share
for the sum of $20,000.  The common stock purchase warrant shall be subject to a
right of  repurchase  by the Company at the purchase  price,  or, if  previously
exercised, the common stock shall be subject to repurchase by the Company at the
exercise price which repurchase rights shall lapse as follows:

                                      -2-
<PAGE>

           o  June 15, 1999   Repurchase  right with  respect to 750,000  shares
                              shall lapse immediately.

           o  June 15, 2000   Repurchase  right with  respect  to an  additional
                              750,000  shares  shall  lapse  (1,500,000  in  the
                              aggregate).

           o  June 15, 2001   Repurchase  right with  respect  to an  additional
                              750,000  shares  shall  lapse  (2,250,000  in  the
                              aggregate).

           o  June 15, 2002   Right to repurchase  with respect to the remaining
                              750,000  shares  shall  lapse  (3,000,000  in  the
                              aggregate).

In addition,  during the time periods  between the  anniversary  dates above the
Company's right to repurchase the warrant or the common stock resulting from the
exercise of the warrants above shall lapse in equal quarterly intervals.

              3.7.   VACATION. The Executive shall be entitled to four (4) weeks
paid vacation per year during the Term, with a maximum accrual of six (6) weeks,
to be taken at a time or times  which  do not  unreasonably  interfere  with his
duties here under.

       4.     TERMINATION.

              4.1.   TERMINATION  UPON DEATH.  If the Executive  dies during the
Term, this Agreement shall terminate as of the date of his death.

              4.2.   TERMINATION  UPON  DISABILITY.  If,  during  the Term,  the
Executive becomes physically or mentally disabled, whether totally or partially,
so that the Executive is unable  substantially to perform his services hereunder
for (i) a period  of three  consecutive  months,  or (ii)  for  shorter  periods
aggregating three months during any twelve-month  period, the Company may at any
time after the last day of the three consecutive months of disability or the day
on which the shorter  periods of disability  equal an aggregate of three months,
by 30  days  written  notice  to  the  Executive,  terminate  the  Term  of  the
Executive's employment hereunder. Nothing in this Section 4.2 shall be deemed to
extend  the  Term.  If the  Term of the  Executive's  employment  is  terminated
pursuant  to this  Section  4.2,  the  Executive  shall be  entitled  to receive
benefits as defined by the terms of the Company long-term  disability  insurance
policy for key executives as in effect in the time of termination.

              4.3.   TERMINATION FOR CAUSE. The Board may terminate  Executive's
employment  for "cause" which for purposes of this  Agreement is defined as: (i)
gross  misconduct in connection with performance of his duties  hereunder;  (ii)
material breach of any undertaking hereunder; or (iii) conviction of, or plea of
nolo contendere to, a felony or any other serious crime or offense.  Termination
is effective on written notice to the Executive.

              4.4.   TERMINATION IN THE DISCRETION OF THE COMPANY. The Board may
terminate  Executive's  employment  without  cause in the sound  exercise of its
discretion. In such event, the Board may: (i) terminate the Executive's right to
enter the premises of the Company by giving notice of such termination, and such
notice shall be effective on the date given pursuant to

                                      -3-
<PAGE>

Section  6.1  hereof;  and  (ii)  by 30 days  written  notice  to the  Executive
thereafter  shall  have only such  right to  receive  monetary  compensation  or
benefits  hereunder  in respect of any period after the  effective  date of such
termination as are provided in Section 4.5.1 hereof.

              4.5.   COMPENSATION ON TERMINATION.

                     4.5.1  If the Term of the Executive's  employment hereunder
is terminated pursuant to Section 4.4 hereof, the Executive shall be entitled to
receive all compensation  accrued and unpaid up to the date of such termination,
plus additional compensation as follows:

           o  Termination prior to June 15, 2000: continued monthly compensation
              for the period from the date of termination  through June 15, 2000
              or six months at the annual  salary rate then in effect  whichever
              total cumulative salary is greater.  Any payments made pursuant to
              this Section  4.5.1 shall be reduced by required  withholdings  or
              authorized deductions.

           o  Termination after June 15, 2000: Six (6) months of compensation at
              the annual salary rate then in effect.  Any payments made pursuant
              to this Section 4.5.1 shall be reduced by required withholdings or
              authorized deductions.

                     4.5.2  If Executive's  employment is terminated pursuant to
Section  4.4 or upon a change of control,  the  Executive  shall be  immediately
entitled to exercise any equity participation  rights (stock options,  warrants,
etc.)  as   provided  in  the   agreement(s)   pursuant  to  which  such  equity
participation  rights  were or are  granted.  For  purposes  of this  Agreement,
"Change of Control" means:  (i) a liquidation or dissolution of the Company,  or
(ii) a merger or consolidation in which the Company is not the surviving entity,
or (iii) a sale of all or substantially  all of the Company" assets,  or (iv) an
acquisition  (other than directly from the Company) by an individual,  entity or
group (excluding the Company or one of its benefit plans or an entity controlled
by the Company's shareholders) of more than 50% of the Company's common stock or
voting securities.

       5.     CERTAIN COVENANTS OF THE EXECUTIVE.

              5.1.   COVENANTS AGAINST COMPETITION.  The Executive  acknowledges
that as of the date  hereof (i) the  principal  business  of the Company and its
affiliates  is the  development  and marketing of Positron  Emission  Tomography
(PET)  Scanners and the related  equipment and computer  programs and "software"
and various  distribution  methods and investment  structures  including imaging
clinics (the  "Company  Business");  (ii) the Company  Business is national (and
international)  in scope; and (iii) his work for the Company has brought him and
will  continue to bring into close  contact with many  confidential  affairs not
readily  available  to the  public,  including  without  limitation,  corporate,
business and financial plans, marketing strategy, product research,  development
and  improvement,  plans for future  development and other matters.  In order to
induce the Company to enter into this  Agreement,  the  Executive  covenants and
agrees:

NON-COMPETE.  During his employment and any period of payment  thereafter,  (the
"Restricted  Period"),  the Executive  shall not in the United States of America
(or in any foreign country),  directly or indirectly,  (i) engage in the Company
Business for his own  account;  (ii) enter the

                                      -4-
<PAGE>

employ of, or render any services to, any person engaged in such activities; and
(iii) become interested in any person engaged in the Company Business,  directly
or  indirectly,  as an  individual,  partner,  shareholder,  officer,  director,
principal,  agent, employee, trustee, consultant or in any other relationship or
capacity; provided, however, that the Executive may own, directly or indirectly,
solely as an  investment,  securities  of any  person  which  are  traded on any
national  securities  exchange if the Executive (a) is not a controlling  person
of, or a member of a group which controls,  such person or (b) does not directly
or indirectly own 5% or more of any class of securities of such person.

                     5.1.1  CONFIDENTIAL  INFORMATION.  The Executive shall keep
secret  and  retain in  strictest  confidence,  and shall not use except for the
benefit  of the  Company  and the  business  and  affairs  of the  Company,  all
confidential  matters  of the  Company  and its  affiliates,  including  without
limitation,  trade "know-how," secrets,  consultant  contracts,  customer lists,
investor  lists,  pricing  policies,  operational  methods,  marketing  plans or
strategies,  product  development or improvement  techniques or plans,  business
acquisition  plans,  new personnel  acquisition  plans,  methods of manufacture,
methods of  manufacture,  technical  processes,  designs  and  design  projects,
inventions and research  projects and other business  affairs of the Company and
its affiliates learned by the Executive or coming into his possession heretofore
or hereafter,  and shall not disclose them to anyone  outside of the company and
its affiliates,  either during or after  employment by the Company or any of its
affiliates,  expect as required in the course of performing  duties hereunder or
with the Company's express prior written consent.

                     5.1.2  PROPERTY  OF  THE   COMPANY.   All   correspondence,
memoranda,  notes,  lists,  records,  computer tapes, discs and design and other
document and data storage and retrieval materials (and all copies,  compilations
and summaries thereof), and all other personal property, made or compiled by the
Executive,  in whole or in part and alone or with  others,  or in any way coming
into his  possession  concerning the business or other affairs of the Company or
any of its affiliates, shall be the Company's property and shall be delivered to
the Company promptly upon the termination of the Executive's employment with the
Company or any of its affiliates for any reason or at any other time on request,
and no copies thereof shall be retained by the Executive.

                     5.1.3  DISCLOSURE AND ASSIGNMENT OF RIGHTS.

                            (A)    The  Executive  agrees that he will  promptly
disclose and assign to the Company and its affiliates or its nominee(s)  (except
as expressly  provided in paragraphs  5.1.4 (C) and (D) below) all right,  title
and  interest  of  the  Executive  in  and to any  and  all  ideas,  inventions,
discoveries,  secret processes and methods, and improvements,  together with any
and all  patents  that may be issued  thereon  in the  United  States and in all
foreign countries,  which the Executive may invent, develop or improve, or cause
to  be  invented,  developed  or  improved,  during  the  Term,  or  during  the
twelve-month  period  commencing  on the  date  the  Executive's  employment  is
terminated pursuant to Section 4.3 hereof, which are (i) conceived and developed
during normal working hours, or

(ii) which are related to the scope of the Company's  Business or are related to
any work carried on by the Company or are related to any  problems  specifically
assigned to the  Executive.  The word "invent" as used herein  includes  "make,"
"discover," "develop,"  "manufacture," or "produce," or any of them; "invention"
includes  the  phrase  "any new or useful  original  art,  machine,  methods  of
manufacture,  process,  composition of matter,  design,  or configuration of any
kind" and the words "improvement,"

                                      -5-
<PAGE>

"discovery"  or  "production,"  or any of them; and "patent"  includes  "Letters
Patent"  and "all the  extensions,  renewals,  modifications,  improvements  and
reissues of such patents."

                            (B)    The Executive agrees to disclose  immediately
to  duly  authorized  representatives  of the  Company  any  ideas,  inventions,
discoveries,  secret  processes  and methods,  and  improvements  covered by the
provisions  of  paragraph  5.1.4(A),  and to execute  all  documents  reasonably
required in connection with the application for an issuance of Letters Patent in
the United States and in all foreign  countries,  and the assignment  thereof to
the Company and its affiliates or its nominee(s).

                            (C)    Set  forth in  Exhibit  A  hereto  is a brief
description of all inventions,  patented and un-patented which the Executive has
made or conceived  prior to his  employment  by the Company  which are expressly
excluded from the provisions of this Agreement.

                            (D)    This   Agreement   does   not   require   the
assignment of any invention which Executive may not be obligated to assign under
Section 2870 of the California Labor Code.

              5.2.   RIGHT AND REMEDIES UPON BREACH. If the Executive  breaches,
or  threatens to commit a breach of, any of the  provisions  of Section 5.1 (the
"Restrictive  Covenants"),  the  Company  shall  have the  following  rights and
remedies,  each of which rights and remedies  shall be  independent of the other
and  severally  enforceable,  and all of which rights and  remedies  shall be in
addition to, and not in lieu of, any other rights and remedies  available to the
Company under law or in equity:

           o  Specific Performance. The right and remedy to have the Restrictive
              Covenant   specifically   enforced  by  any  court  having  equity
              jurisdiction,  including  without  limitation,  the  granting of a
              preliminary injunction which may be granted without the posting of
              a bond or other security,  it being  acknowledged  and agreed that
              any such breach or threatened breach will cause irreparable injury
              to the Company and that money damages will not provide an adequate
              remedy to the Company.

              5.3.   SEVERABILITY OF COVENANTS. If any court determines that any
of the Restrictive Covenants,  or any part thereof, is invalid or unenforceable,
the  remainder of the  Restrictive  Covenants  shall not thereby be affected and
shall be given full effect, without regard to the invalid portions.

              5.4.   BLUE   PENCILING.   If  any  court  construes  any  of  the
Restrictive  Covenants,  or any part thereof, to be unenforceable because of the
duration of such  provision or the area covered  thereby,  such court shall have
the  power to  reduce  the  duration  of the  area of or  otherwise  alter  such
provision and, in its reduced form, such provision shall then be enforceable and
shall then be enforced.

              5.5.   ENFORCEABILITY  IN JURISDICTION.  The parties intend to and
hereby confer jurisdiction to enforce the Restrictive  Covenants upon the courts
of any  jurisdiction  within the  geographical  scope of such Covenants.  If the
courts of any one or more of such jurisdictions

                                      -6-
<PAGE>

hold the Restrictive  Covenants wholly  unenforceable by reason of the breath or
scope or otherwise,  it is the intention of the parties that such  determination
not bar or in any way effect the Company's right to the relief provided above in
the  courts of any other  jurisdiction  within  the  geographical  scope of such
Covenants  as  to  breaches  of  such   Covenants   in  such  other   respective
jurisdictions,  such Covenants as they relate to each  jurisdiction  being,  for
this purpose, severable into diverse and independent covenants.

       6.     MISCELLANEOUS.

              6.1.   NOTICES.  Any  notice or other  communication  required  or
which  may be  given  hereunder  shall be in  writing  and  shall  be  delivered
personally,   telegraphed,   telexed,  or  telecopies,  or  sent  by  certified,
registered or express mail,  postage prepaid,  and shall be deemed given when so
delivered personally, telegraphed, telexed or telecopied, or if mailed, two days
after the date of mailing, as follows:

           o  If to the Company, addressed to it at:

              Positron Corporation
              1304 Langham Creek, #300
              Houston, Texas  77084

           o  If to the Executive,  addressed to him at such address as he shall
              have  filed  with the  Company  for such  purpose or at such other
              address as a party may from time to time specify by giving  notice
              as provided herein.

              6.2.   ENTIRE  AGREEMENT.  Subject to  Section  3.6  hereof,  this
Agreement  contains the entire agreement between the parties with respect to the
subject matter hereof and supersedes all prior agreements, written or oral, with
respect thereto.

              6.3.   WAIVERS  AND  AMENDMENTS.  This  Agreement  may be amended,
modified,  superseded,   canceled,  renewed  or  extended,  and  the  terms  and
conditions  hereof may be waived,  only by a written  instrument  signed by both
parties or, in the case of a waiver, by the party waiving  compliance.  No delay
on the part of any party in exercising any right,  power or privilege  hereunder
shall operate as a waiver thereof, nor shall any waiver on the part of any party
of any right, power or privilege  hereunder,  nor any single or partial exercise
of any  right,  power or  privilege  hereunder  preclude  any  other or  further
exercise  thereof  or the  exercise  of any  other  right,  power  or  privilege
hereunder.

              6.4.   ASSIGNMENT.  This  Agreement is personal to the  Executive,
and the Executive's rights and obligations  hereunder may not be assigned by the
Executive.  The Company may assign this Agreement and its rights,  together with
its  obligations  hereunder  in  connection  with any  sale,  transfer  or other
disposition of all or substantially  all of its assets or business(es),  whether
by merger, consolidation or otherwise.

              6.5.   COUNTERPARTS. This Agreement may be executed in two or more
counterparts,  each of  which  shall  be  deemed  an  original  but all of which
together shall constitute one and the same instrument.

                                      -7-
<PAGE>

              6.6.   HEADINGS.  The section  headings in this  Agreement are for
reference  purposes  only  and  shall  not in any  way  affect  the  meaning  or
interpretation of this Agreement.

       IN WITNESS WHEREOF,  the parties have executed this Executive  Employment
Agreements as of the date first above written.

/s/ Gary H. Brooks                       /s/ S. Lewis Meyer
--------------------------------------   ---------------------------------------
EXECUTIVE                                POSITRON CORPORATION

Date: Sept. 1, 1999                      Date: Sept 1, 1999
     ---------------------------------        ----------------------------------

                                      -8-EXHIBIT 10.62

                              AGREEMENT AND RELEASE

       THIS AGREEMENT AND RELEASE ("Agreement") is entered into this 29th day of
November,  1999  by  and  between  Positron  Corporation,  a  Texas  corporation
("Positron") and K. Lance Gould, M. D. ("Gould").

                                R E C I T A L S :
                                 - - - - - - - -

       1.     Positron  and  Gould  previously  have  entered  into a series  of
agreements, including:

              a.     Amended and Restated License Agreement dated as of June 30,
1987  by  and  among  Positron,  Gould,  the  Clayton  Foundation  for  Research
("Clayton")   and  Nizar  A.  Mullani   ("Mullani")   regarding  the  ownership,
manufacturing and marketing of certain proprietary  property relating to medical
imaging,  design and  construction  of positron  imaging  cameras and associated
equipment for medical and diagnostic applications ("License Agreement");

              b.     Royalty Exchange Agreement dated as of June 30, 1987 by and
between Positron and Gould;

              c.     Royalty  Assignment  dated as of  December  22, 1988 by and
between Positron and Gould pursuant to which Gould sold to Positron one-third of
his  royalty  interest  under  the  License  Agreement  for good and  sufficient
consideration ("Gould Royalty Assignment");

              d.     Clarification  Agreement  dated as of December  22, 1988 by
and among  Positron,  Gould,  Clayton and Mullani  clarifying  certain terms and
conditions  set  forth in the  Gould  Royalty  Assignment  and  related  Royalty
Assignments ("Clarification Agreement");

              e.     Master  Agreement  dated  as of  January  15,  1993  by and
between Positron and Gould ("Master Agreement");

              f.     Consulting  Agreement  dated as of January  15, 1993 by and
between  Positron and Gould  pursuant to which Gould  agreed to provide  certain
consulting services to Positron under certain terms and conditions  ("Consulting
Agreement");

              g.     Letter Agreement dated May 19, 1993 by and between Positron
and Gould  amending the Master  Agreement  and  Consulting  Agreement in certain
respects and confirming certain  obligations  existing between the parties as of
that date (" 1993 Letter Agreement");

<PAGE>

              h.     Two  convertible  promissory  notes dated as of October 31,
1993  indicating  Gould as Borrower  and  Positron as Holder,  in the  principal
amounts of $138,593.63 and $281,250.00 respectively,  plus interest ("Promissory
Note(s)");

              i.     Agreement  by and  between  Positron  and Gould dated as of
November  15,  1993  amending  certain  provisions  of the  Promissory  Notes to
automatically  convert the principal amounts of the Promissory Notes to Positron
common stock  pursuant to an agreed  formula and further,  clarifying the rights
and  obligations  of the  parties in the event of certain  defined  defaults  by
Positron, and certain other agreements ("Conversion Agreement"); and

              j.     Letter Agreement by and between Positron and Gould dated as
of December 16, 1998  regarding  modifications  to some or all of the agreements
listed above ("1998 Letter Agreement").

       2.     Positron  and Gould now wish to  resolve  any and all  differences
between  them arising out of the above listed  agreements  or any other  matter,
without  dispute,  and to agree  on terms  and  conditions  of their  continuing
relationship, all pursuant to the terms and conditions set forth below.

       NOW THEREFORE, for good and sufficient  consideration,  the parties agree
as follows:

                                    AGREEMENT

       1.     ROYALTIES,  DIRECTOR FEES,  CONSULTING  FEES AND ANY OTHER SERVICE
FEES.  Positron owes to Gould certain sums in past due royalties pursuant to the
agreements listed above in Recital 1, which amounts have not been paid. Further,
Positron owes to Gould certain sums in fees for serving as a member of the board
of directors, as a consultant and/or for other services,  which amounts have not
been paid. On the other hand,  Gould owes to Positron  certain sums of principal
and interest  under the Promissory  Notes,  which amounts have not been paid and
which  Promissory  Notes are  secured  by  Positron  common  stock.  In full and
complete  settlement of all  royalties  payable by Positron to Gould through the
date of this Settlement  Agreement,  and further in full and complete settlement
of any and all sums  which  may be  payable  by  Positron  to Gould for fees for
serving  as a  member  of the  board  of  directors  or as a  consultant  or for
providing any other services through the date of this Agreement,  and further in
full and complete  settlement of all sums of principal and interest  which Gould
may owe to Positron under the Promissory Notes, the parties agree as follows:

              (a)    Positron  will pay to Gould the sum of $38,872 as  promptly
as  possible,  but in no  event  later  than  fifteen  business  days  following
execution of this Agreement.

              (b)    Positron  grants to Gould,  and will  instruct its transfer
agent to issue to Gould,  168,000 shares of Positron  unregistered common stock,
to be issued as promptly as practicable following execution of this Agreement.

              (c)    On and  after  the  date  of  this  Agreement,  any and all
royalties  payable by Positron to Gould pursuant to the License  Agreement,  the
Royalty Assignment,  or pursuant to any other agreements listed above in Recital
1, shall be calculated at the rate of one percent (1%) of gross revenues derived
from the  initial  sale,  use,  lease,  licensing  or rental of the  Proprietary

                                      -2-
<PAGE>

Property as set forth in the License Agreement. In addition to any other waivers
and releases set forth in this Agreement, Gould waives any and all demand rights
he may have,  pursuant  to the  Conversion  Agreement  or any  other  agreement,
regarding  increasing  the  royalty  payments  otherwise  due and  payable  from
Positron to Gould from 1% to 1.5%.

              (d)    The parties further agree that Gross  Revenues,  as used in
the License Agreement and in this Agreement, serves as the basis for calculating
royalties payable to Gould, and shall be defined as revenues actually  collected
by  Positron,  less:  (i) cash or trade  discounts;  (ii)  credits for return of
defective  or  trade-in  products;  (iii)  sales  and  use  taxes;  and/or  (iv)
transportation charges. The foregoing notwithstanding, the parties further agree
that Gross  Revenues  does not  include,  and is not  intended to  include:  (v)
maintenance   charges;   (vi)  service  revenue;   (vii)  revenue  derived  from
pass-through  sales of other  components and third party  vendors'  software and
operating systems;  and/or (viii) resale of refurbished products previously sold
and thereafter returned to the Company and on which royalties were paid based on
the prior sale.

       2.     FUTURE SERVICES. Positron seeks to encourage Gould to continue his
work in  developing  clinical  software and to provide  additional  know-how and
proprietary property to the Company as it relates to the clinical application of
PET  technology  in  cardiology.   Further,  Positron  seeks  to  encourage  the
University of Texas PET Imaging Center to support  Gould's  efforts to do so. In
order to provide this  encouragement to their mutual benefit,  the parties agree
as follows:

              (a)    Positron will provide to Gould original source code for all
the software and cardiology algorithms  ("Software") currently developed for and
in use with the PET system currently utilized by Gould in the PET Imaging Center
at the  University of Texas  ("University  PET System").  A list of the Software
components  intended  to be covered  by this  limited  non-exclusive  license is
attached  hereto as  Attachment  A. Such Software is provided for the purpose of
supporting  the  research  activities  engaged in directly  and/or  specifically
directed by Gould at the  University's  PET Imaging Center.  The original source
code for such  Software is  provided on  condition  that  neither  Gould nor the
University  will use the Software,  or any derivative  thereof,  for any purpose
other than the research and development  purposes set forth herein  ("Acceptable
Purposes")  and further on  condition  that Gould will  provide to Positron  the
source code for any and all enhancements  made to the Software  pursuant to this
license . Acceptable Purposes  specifically  exclude any commercial use, sale or
distribution whatsoever of the Software or any derivative,  or other transfer of
the Software or any  derivative  to any third person for other than research and
development  purposes,  or use by Gould and/or the University of the software or
any  derivative  for other  than an  Acceptable  Purpose  as it  relates  to the
clinical   application   of  PET   technology  in   cardiology.   The  foregoing
notwithstanding,  the parties agree that Acceptable Purposes" includes utilizing
the Software at other  Positron  centers using Positron PET machines and related
equipment.

              (b)    Gould will  provide  and  deliver to  Positron  any and all
software    developments,     derivatives,    and/or    protocol    developments
("Enhancements") he prepares or develops with or from the Software.  Positron is
authorized to and will use such Enhancements in or as part of its business,  and
will include such Enhancements in the Proprietary  Property to which the License
Agreement and this Agreement apply.

                                      -3-
<PAGE>

              (c)    Gould agrees to serve on Positron's Medical Advisory Board,
at no  additional  charge or fee, for a minimum of three (3) years from the date
of this Agreement  ("Service  Period").  During the Service Period,  Gould shall
devote  such time and effort as is mutually  agreed by Gould and  Positron to be
appropriate  and  necessary  to achieve  the  purposes  of such  service,  which
purposes  are  deemed  to be the  enhancement  of  clinical  utilization  of PET
technology in cardiology.

              (d)    To encourage the  University to allow Gould to continue his
research and development activities as contemplated by this Agreement,  Positron
agrees to provide to the  University  PET  Imaging  Center,  and the  University
accepts pursuant to the conditions set forth herein,  for a period of five years
from the effective date of this Agreement  ("Maintenance  Period"),  maintenance
services  regarding the POSICAM (TM) PET System at no charge for labor. Costs of
hardware  components will be charged at Positron's cost. At Positron's  request,
the  University  will  advance  or  otherwise  pay the costs to obtain  hardware
components  necessary to provide the maintenance  services  contemplated herein.
Further,  Positron will continue during the Maintenance Period to provide to the
University any software  upgrades and other software  enhancements to the system
as it  typically  provides  to other  third  party  maintenance  customers,  and
University  agrees  to and will  execute  Positron's  standard  maintenance  and
service  agreement  consistent  with the terms herein.  University  specifically
waives any rights to any and all rights to any software, derivatives,  know-how,
or  proprietary  property  developed  either by Positron or by Gould  during the
Maintenance Period.

       The foregoing  notwithstanding,  the provisions of this  subsection  3(d)
shall have no force and effect  unless and until the  University of Texas and/or
the University of Texas Health Science  Center at Houston  agrees,  acknowledges
and approves this Agreement.

       3.     ISSUANCE AND REGISTRATION OF COMMON STOCK.

              (a)    Gould  represents  and warrants  that he is  acquiring  the
common stock pursuant to this Agreement for his own account for investment  only
and not with a view towards,  or for resale in connection  with, the public sale
or distribution  thereof,  except pursuant to sales registered or exempted under
the 1933  Securities  Act.  Gould further  represents and warrants that he is an
"accredited  investor" as that term is defined in Rule 501(a)(3) of Regulation D
as promulgated by the SEC.

              (b)    Positron  agrees to include the common  stock  delivered in
connection  with this  Agreement,  as well as any other  Positron  common  stock
currently held by Gould in his name, in the next registration statement Positron
files  with the  Securities  and  Exchange  Commission  ("SEC")  relating  to an
offering for its own account or the account of others under the 1933  Securities
Act (other  than on Form S-4 or Form S-8 or their then  equivalents  relating to
securities to be issued solely in connection  with any acquisition of any entity
or business or equity  securities  issuable in  connection  with stock option or
other employee benefit plans).  If the registration  referred to herein is to be
an  underwritten  public  offering  for the account of Positron and the managing
underwriter(s)  determine,  in  their  reasonable  good  faith  opinion,  that a
limitation  on the number of shares of common stock which may be included in the
registration  statement is necessary to facilitate and not adversely  affect the
proposed offering,  then Positron will include the common stock held by Gould in
the next  registration  statement  Positron

                                      -4-
<PAGE>

thereafter files with the SEC. The foregoing notwithstanding, Positron agrees to
include the common stock delivered in connection with this Agreement, as well as
any other Positron common stock currently held by Gould in his name, in the next
registration  statement  relating to an offering for the account of others under
the 1933 Securities Act.

       4.     RELEASE OF CLAIMS.

              (a)    Positron  (on  behalf  of  and  including  its   respective
officers,   directors,   shareholders,    employees,   agents,   administrators,
representatives,  successors  and assigns,  in the aggregate  "Positron  Related
Parties")  on the one hand,  and Gould (on behalf of and  including  his marital
community, agents,  administrators,  representatives,  executors and assigns, in
the  aggregate  "Gould  Related  Parties")  on the other hand,  hereby  mutually
release and discharge each other and their  respective  Related Parties from all
liability,  claims,  demands,  actions,  or  causes  of  action  of any  kind or
character,  whether fixed or contingent (collectively "Claims") arising from the
beginning  of time to the date of this  Agreement,  and from  whatever  sources,
including but not limited to claims relating to any of the agreements  listed in
Recital I to this  Agreement,  except for any provisions  that by their specific
terms are  intended to survive  termination  of the  respective  agreement,  and
except for the provisions of this Agreement.

              (b)    Positron  and Gould  understand  and  acknowledge  that the
provisions of this Section 6 and of Section 1 above are intended to and do apply
to and  include  all known and unknown or  unsuspected  consequences  or results
arising from or relating to the  transactions,  occurrences or agreements listed
in Recital 1. Positron and Gould,  on behalf of themselves and their  respective
Related  Parties  represent  and warrant that the  releases of claims  contained
herein are intended to be full and general  releases,  and they hereby expressly
waive any and all rights and  benefits  under any  statute or  principal  of law
reserving any rights to any claims which Positron  and/or Gould or either one of
them does not know or suspect to exist in its/his favor at the time of executing
the release,  and which, if known by it/him,  must have materially affected this
settlement and release.

              (c)    Positron and Gould each hereby  acknowledges that it/he has
read  this  Agreement,  that  it/he  fully  understands  the  contents  of  this
Agreement,  and that this is a GENERAL  RELEASE giving up rights with respect to
the agreements,  transactions or occurrences  that are being released under this
Agreement.

       5.     RESOLUTION OF DISPUTES.

              (a)    The  parties  shall  submit all  disputes  relating to this
Agreement, or any agreement listed on Recital 1 (whether contract, tort or both)
to binding arbitration in accordance with the rules of the American  Arbitration
Association  ("AAA")  relating to resolution  of  commercial  disputes in Harris
County,  Texas or otherwise as mutually agreed. The parties understand and agree
that they are waiving their rights to a jury trial.

              (b)    The  party  demanding  arbitration  shall  submit a written
claim to the other party,  setting out the basis of the claim and  proposing the
name of an arbitrator. The responding party shall have twenty (20) business days
in which to respond to the demand in a written  answer.  If the  response is not
timely  made,  or if the  responding  party  agrees with the person

                                      -5-
<PAGE>

proposed as  arbitrator  by the  demanding  party,  then the person named by the
demanding  party shall serve as arbitrator.  If the  responding  party submits a
written answer rejecting the proposed  arbitrator then, unless the parties agree
on an arbitrator,  an arbitrator  will be selected  pursuant to the rules of the
AAA.  Within  fifteen  (15)  days  after  completion  of  the  arbitration,  the
arbitrator will submit a decision in writing. Before arbitration commences, each
party shall pay the arbitrator half of the expected cost of the arbitration.  At
the conclusion of the arbitration, the arbitrator may award the prevailing party
some or all of the  arbitration  costs, as well as some or all of the prevailing
party's other expenses,  including reasonable attorney fees and witness fees, in
such proportion as the arbitrator deems appropriate. Unless otherwise determined
by the arbitrator,  each side shall bear its own expenses other than the cost of
arbitration, which shall be split.

       6.     MISCELLANEOUS.

              (a)    All notices,  requests,  demands,  or other  communications
under this Agreement shall be in writing. Notice shall be sufficiently given for
all purposes if delivered personally (upon receipt),  by first class mail (three
mail delivery days after  deposit),  by certified mail (upon  receipt,  delivery
confirmed by return  receipt),  overnight  delivery  (upon  receipt,  by Federal
Express or comparable  carrier,  charges prepaid or charged to sender's account,
delivery confirmed by carrier),  or by facsimile  transmission (upon receipt, if
delivery confirmed by notice), to the following:

       If to Positron:

              1304 Langham Creek Drive, Suite 300
              Houston, Texas   77084
              Attn:  President
              Phone: 281-492-7100 x 208 (Main)
              1-281-492-2961 (Fax)

       If to Gould:

              2330 Albans
              Houston, Texas 77005
              Phone: 713-500-6611
              Fax:   713-500-6615

              (b)    This  Agreement  may be modified or amended  only by mutual
agreement and in writing, signed by the party to be charged.

              (c)    This  Agreement,   including   exhibits  and   attachments,
constitutes  the final,  complete  and  exclusive  statement of the terms of the
agreement  between the parties  pertaining  to the subject  matter  herein,  and
supercedes  all prior and  contemporaneous  understandings  or agreements of the
parties.  No party has been induced to enter into this  Agreement by, nor is any
party relying on, any  representation  or warranty  outside those  expressly set
forth in this Agreement.

                                      -6-
<PAGE>

              (d)    The parties  hereto  agree that each of them will use their
best  reasonable  efforts to obtain the approval of the Health Science Center of
the provisions of this  Agreement.  The parties further agree that if the Health
Science  Center does not  formally  approve the  provisions  of this  Agreement,
Positron's  maintenance  obligations  as set forth in ss. 3(d) herein  shall not
take effect,  but the  provisions of this  Agreement as they relate to Gould and
Positron  shall be binding  and inure to the  benefit  those  parties  and their
respective heirs, executors, administrators, assigns and successors in interest.

              (e)    This Agreement may be executed in several  counterparts and
by facsimile transmission,  each of which shall be deemed an original but all of
which shall constitute one instrument binding on all parties.

       AGREED to this 29th day of November, 1999.

                                        POSITRON CORPORATION

                                        By: [ORIGINAL SIGNED: Gary H. Brooks
                                        Its: President

                                        [ORIGINAL SIGNED]
                                        K. LANCE GOULD, M.D.

       AGREED, ACKNOWLEDGED AND APPROVED this 16th day of December, 1999.

                                        UNIVERSITY OF TEXAS HEALTH SCIENCE
                                        CENTER AT HOUSTON

                                        By: [ORIGINAL SIGNED]

                                        Its: Executive Vice President
                                            ------------------------------------

                                      -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]